exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275860 RNA Name: hsa-miR-625-5p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 65471116 End Site(bp): 65471136 External Links: hsa-miR-625-5p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand PPP2R1A chr19 52190048 52229518 + SF3B3 chr16 70523791 70577670 + LRFN1 chr19 39306568 39315336 - SLC6A6 chr3 14402576 14489349 + VPS37B chr12 122865330 122896127 - SMARCC2 chr12 56162359 56189567 - WIZ chr19 15419978 15449956 - SLC7A5 chr16 87830023 87869507 - MED22 chr9 133338312 133348131 - PPARD chr6 35342558 35428191 + FAM102A chr9 127940582 127980989 - ABL2 chr1 179099330 179229684 - PPP6C chr9 125146573 125189939 - ABCF2 chr7 151207837 151227166 - ABHD14A-ACY1 chr3 51974706 51989183 + BCL9L chr11 118893875 118925608 - JUN chr1 58780791 58784047 - NUMB chr14 73275107 73458617 - SDF2 chr17 28648346 28662189 - SREBF2 chr22 41833079 41907307 + COL6A2 chr21 46098112 46132848 + ACY1 chr3 51983340 51989197 + E2F1 chr20 33675477 33686385 - PRDX2 chr19 12796820 12801800 - MSI1 chr12 120341330 120369164 - COPS7B chr2 231781671 231809254 + CPSF7 chr11 61402641 61430031 - SCAMP4 chr19 1905372 1926013 + ITGA5 chr12 54395261 54419266 - RNF44 chr5 176526712 176538025 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001434 chr4 106345352 106377902 - hsa_circ_0001409 chr4 48835417 48859382 + hsa_circ_0001358 chr3 169694733 169706147 + hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC010542.4 chr16 66549280 66551189 + AC145207.5 chr17 81878425 81881106 - AC234582.1 chr1 155195004 155205495 + H19 chr11 1995176 2001470 - LINC00240 chr6 26956932 27059749 + MALAT1 chr11 65497688 65506516 + SNHG7 chr9 136721366 136728184 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.